ArticleAnnals of surgical oncology2017
Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas (IPMN) Under Surveillance: A Single-Institution Experience.
Article in Annals of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02078245 (Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Guideline
- Decision Modeling to Guide Management of Pancreatic IPMNs: Immediate Surgery or Initial Surveillance?Annals of surgical oncology · 2026Article
- Imaging-Based Risk Stratification of IPMN Using a Structured Imaging Score: A Retrospective Proof-of-Concept Study.Current oncology (Toronto, Ont.) · 2026Article
- Evaluating the Kyoto Guidelines' Worrisome Features and High-Risk Stigmata to Predict High-Grade Dysplasia and Invasive Cancer in Intraductal Papillary Mucinous Neoplasms.Annals of surgical oncology · 2026Article
- Value of Intraoperative Pancreatoscopy in Patients Undergoing Resection for Main-Duct Intraductal Papillary Mucinous Neoplasm: Thirty-Day Follow-Up of a Prospective International Study.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2026Article
- Pancreatic Cystic Lesions: From Basic Knowledge to Recent Guidelines.Journal of clinical medicine · 2026Review
- Mutant GNAS drives a pyloric metaplasia with tumor suppressive glycans in intraductal papillary mucinous neoplasia.Cell reports · 2025Article
- Pancreatic Cystic Lesions in the Older Patient: A Review of Clinical Guidelines and Management.Current gastroenterology reports · 2025Review
- Artificial intelligence in pancreatic intraductal papillary mucinous neoplasm imaging: A systematic review.PLOS digital health · 2025Article
- Assessing Follow-Up Duration in Intraductal Papillary Mucinous Neoplasm Patients.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Current Considerations in Nonoperative Surveillance of Intraductal Papillary Mucinous Neoplasms.Digestive disease interventions · 2025Article
- Histological Subtypes Might Help Risk Stratification in Different Morphological Types of IPMNs: Back to the Future?Journal of clinical medicine · 2024Article
- [Pancreatic cystic neoplasms].Chirurgie (Heidelberg, Germany) · 2024Review
- Rare tumours of the pancreas: monocentric study.Journal of cancer research and clinical oncology · 2024Article
- Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms.Nature communications · 2024Article
- Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features.Journal of surgical oncology · 2023Observational
- Minimally invasive enucleation of pancreatic tumors: The main pancreatic duct is no longer a restricted area.Heliyon · 2023Article
- Pancreatic Intraductal Papillary Mucinous Neoplasms: A Narrative Review.Acta medica Lituanic · 2023Review
- Single-operator peroral pancreatoscopy in the preoperative diagnostics of suspected main duct intraductal papillary mucinous neoplasms: efficacy and novel insights on complications.Surgical endoscopy · 2022Article
- Should non-invasive diffuse main-duct intraductal papillary mucinous neoplasms be treated with total pancreatectomy?HPB : the official journal of the International Hepato Pancreato Biliary Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhile surveillance of the majority of patients with IPMN is considered best practice, consensus regarding the duration of follow-up is lacking. This study assessed the survival rate and risk for progression of IPMN under surveillance.
methodsAll patients diagnosed with and surveyed for IPMN between January 2008 and December 2013 were identified and assigned to two groups: patients without indication for surgery (Group 1), and patients whose IPMN required surgery but were inoperable for general reasons (Group 2). Disease progression and survival data were compared between both groups.
resultsIn total 503 patients were identified, of whom 444 (88.3%) were followed up. Group 1 included 395 patients, and Group 2 had 49. In Group 1, IPMN-specific 1-, 5-, and 10-year survival rates were 100, 100, and 94.2%, respectively. Four patients died of associated or concomitant pancreatic cancer, and 230 patients (58.2%) experienced disease progression. The 1-, 4-, 10-year cumulative risk for progression and for surgery was 11.2, 70.6, 97.5, and 2.9, 26.2, 72.1%, respectively. In Group 2, the 1-, 5-, 10-year IPMN-specific survival rate was 90.7, 74.8, and 74.8%, respectively.
conclusionsThis study confirmed the safety of surveillance for patients with IPMN who do not require surgery. However, the risk for disease progression and for surgery increases significantly over time. The study results support International and European guidelines not to discontinue IPMN surveillance and validate the European recommendation to intensify follow-up after 5 years. The fairly good prognosis of patients whose IPMN requires surgery but cannot undergo resection suggests a relatively indolent disease biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.